10-Q quarterly report · filed Nov 5, 2026

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 10-Q Quarterly Report

Short answer

Arcturus Therapeutics Holdings Inc. (ARCT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $18M (up 6.7% year over year) with net income of −$7M.

Q3 2026 key financials · XBRL

Revenue
$18M
+6.7% YoY · +518.4% QoQ
Net income
−$7M
+44.9% YoY · +68.8% QoQ
Operating margin
-50.2%
EPS (diluted)
−$0.26
+46.9% YoY · +69.0% QoQ

Source: XBRL data from the Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 10-Q on SEC EDGAR. USD.

Arcturus Therapeutics Holdings Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $18.3M, up $1.1M YoY from $17.2M, driven by $16.8M CSL termination-related collaboration revenue
  • Collaboration revenue $16.9M vs $14.2M; grant revenue $1.4M vs $3.0M, down 52% YoY
  • Operating expenses $27.5M, down 18% YoY, including R&D $17.0M vs $23.3M
  • Cash $184.8M at September 30; nine-month operating cash use $46.3M vs $58.0M
  • Outlook: cash expected sufficient through at least next twelve months; additional capital anticipated, with continued losses and clinical-development spending

Risk Factors

  • CSL Seqirus termination: Arcturus now funds vaccine programs without milestone payments, research funding, or profit sharing
  • KOSTAIVE Japan transition: CSL Seqirus and Meiji remain responsible through June 30, 2027, creating transfer disruption risk
  • myNEO acquisition: Integration requires compliance with Belgian data privacy, employment, and tax laws
  • myNEO acquisition: Unregistered shares and potential milestone shares may dilute existing stockholders
  • Middle East conflicts: Regional disruptions could affect international clinical sites, including Israel

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Arcturus Therapeutics Holdings Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.